The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 583-585
10.1182/blood-2022-157949